American Health & Drug Benefit recently published an article co-authored by our CEO, Lisa Bloudek. The article discusses the cost implications of adopting intravenous cetirizine in an emergency department setting to treat acute urticaria from a hospital perspective.
To access the full publication, visit:
https://www.ahdbonline.com/issues/2022/september-2022-vol-15-no-3/3239-budget-impact-of-intravenous-cetirizine-hydrochloride-for-the-treatment-of-acute-urticaria-in-the-emergency-department-setting.